Lederer DJ, Martinez FJ (2018) Idiopathic Pulmonary fibrosis. N Engl J Med 10(19):1811–1823. https://doi.org/10.1056/NEJMra1705751

Article  Google Scholar 

D’Agnano V, Perrotta F, Fomez R, Carrozzo VM, Schiattarella A, SanduzziZamparelli S, Pagliaro R, Bianco A, Mariniello DF (2024) Pharmacological treatment of interstitial lung diseases: a novel landscape for inhaled agents. Pharmaceutics 16(11):1391. https://doi.org/10.3390/pharmaceutics16111391

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yoshikawa T, Otsuka M, Chiba H, Ikeda K, Mori Y, Umeda Y, Nishikiori H, Kuronuma K, Takahashi H (2020) Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. https://doi.org/10.1186/s12890-020-1060-y

Article  PubMed  PubMed Central  Google Scholar 

Ikeda K, Chiba H, Nishikiori H, Azuma A, Kondoh Y, Ogura T, Taguchi Y, Ebina M, Sakaguchi H, Miyazawa S, Suga M, Sugiyama Y, Nukiwa T, Kudoh S, Takahashi H, Pirfenidone Clinical Study Group in Japan (2020) Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan. Respir Res 21(1):316. https://doi.org/10.1186/s12931-020-01582-y

Article  PubMed  PubMed Central  CAS  Google Scholar 

Todd JL, Vinisko R, Liu Y, Neely ML, Overton R, Flaherty KR, Noth I, Newby LK, Lasky JA, Olman MA, Hesslinger C, Leonard TB, Palmer SM, Belperio JA, IPF-PRO Registry investigators (2020) Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO registry cohort. BMC Pulm Med 20(1):64. https://doi.org/10.1186/s12890-020-1103-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

Korthagen NM, van Moorsel CH, Barlo NP, Ruven HJ, Kruit A, Heron M, van den Bosch JM, Grutters JC (2011) Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir Med 105(1):106–113. https://doi.org/10.1016/j.rmed.2010.09.012

Article  PubMed  Google Scholar 

Tsoutsou PG, Gourgoulianis KI, Petinaki E, Mpaka M, Efremidou S, Maniatis A, Molyvdas PA (2004) ICAM-1, ICAM-2 and ICAM-3 in the sera of patients with idiopathic pulmonary fibrosis. Inflammation 28(6):359–364. https://doi.org/10.1007/s10753-004-6647-6

Article  PubMed  CAS  Google Scholar 

Ma HY, Li Q, Wong WR, N’Diaye EN, Caplazi P, Bender H, Huang Z, Arlantico A, Jeet S, Wong A, Emson C, Brightbill H, Tam L, Newman R, Roose-Girma M, Sandoval W, Ding N (2023) LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung. Sci Adv. https://doi.org/10.1126/sciadv.adf0133

Article  PubMed  PubMed Central  Google Scholar 

Okamoto M, Fujimoto K, Johkoh T, Kawaguchi A, Mukae H, Sakamoto N, Ogura T, Ikeda S, Kondoh Y, Yamano Y, Komiya K, Umeki K, Nishikiori H, Tanino Y, Tsuda T, Arai N, Komatsu M, Sakamoto S, Yatera K, Inoue Y, Miyazaki Y, Hashimoto S, Shimizu Y, Hozumi H, Ohnishi H, Handa T, Hattori N, Kishaba T, Kato M, Inomata M, Ishii H, Hamada N, Konno S, Zaizen Y, Azuma A, Suda T, Izuhara K, Hoshino T (2023) A prospective cohort study of periostin as a serum biomarker in patients with idiopathic pulmonary fibrosis treated with nintedanib. Sci Rep 13(1):22977. https://doi.org/10.1038/s41598-023-49180-4

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lee JU, Chang HS, Shim EY, Park JS, Koh ES, Shin HK, Park JS, Park CS (2020) The S100 calcium-binding protein A4 level is elevated in the lungs of patients with idiopathic pulmonary fibrosis. Respir Med 171:105945. https://doi.org/10.1016/j.rmed.2020.105945

Article  PubMed  Google Scholar 

Perrotta F, D’Agnano V, Mariniello DF, Castaldo G, Vitale M, Cazzola M, Bianco A, Scialò F (2024) Potential role of SIRT-1 and SIRT-3 as biomarkers for the diagnosis and prognosis of idiopathic pulmonary fibrosis. Respir Res 25(1):189. https://doi.org/10.1186/s12931-024-02796-0

Article  PubMed  PubMed Central  CAS  Google Scholar 

D’Agnano V, Scialò F, Perna F, Atripaldi L, Sanduzzi S, Allocca V, Vitale M, Pastore L, Bianco A, Perrotta F (2022) Exploring the role of krebs von den Lungen-6 in severe to critical COVID-19 patients. Life (Basel) 12(8):1141. https://doi.org/10.3390/life12081141

Article  PubMed  CAS  Google Scholar 

Vianello A, Guarnieri G, Achille A, Lionello F, Lococo S, Zaninotto M, Caminati M, Senna G (2023) Serum biomarkers of remodeling in severe asthma with fixed airway obstruction and the potential role of KL-6. Clin Chem Lab Med 30(61):1679–1687. https://doi.org/10.1515/cclm-2022-1323

Article  CAS  Google Scholar 

Bennett D, Salvini M, Fui A, Cillis G, Cameli P, Mazzei MA, Fossi A, Refini RM, Rottoli P (2019) Calgranulin B and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP. Inflammation 42(2):463–470. https://doi.org/10.1007/s10753-018-00955-2

Article  PubMed  CAS  Google Scholar 

Zhang L, Wang Y, Wu G, Xiong W, Gu W, Wang CY (2018) Macrophages: friend or foe in idiopathic pulmonary fibrosis? Respir Res 19(1):170. https://doi.org/10.1186/s12931-018-0864-2

Article  PubMed  PubMed Central  CAS  Google Scholar 

Geng J, Liu Y, Dai H, Wang C (2022) Fatty acid metabolism and idiopathic pulmonary fibrosis. Front Physiol 14(12):794629. https://doi.org/10.3389/fphys.2021.794629

Article  Google Scholar 

Schmidt R, Meier U, Markart P, Grimminger F, Velcovsky HG, Morr H, Seeger W, Günther A (2002) Altered fatty acid composition of lung surfactant phospholipids in interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 283(5):L1079–L1085. https://doi.org/10.1152/ajplung.00484.2001

Article  PubMed  CAS  Google Scholar 

Kim HS, Yoo HJ, Lee KM, Song HE, Kim SJ, Lee JO, Hwang JJ, Song JW (2021) Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis. Respirology 26(3):255–263

Article  PubMed  Google Scholar 

Chu SG, Villalba JA, Liang X, Xiong K, Tsoyi K, Ith B, Ayaub EA, Tatituri RV, Byers DE, Hsu FF, El-Chemaly S, Kim EY, Shi Y, Rosas IO (2019) Palmitic acid-rich high-fat diet exacerbates experimental pulmonary fibrosis by modulating endoplasmic reticulum stress. Am J Respir Cell Mol Biol 61(6):737–746. https://doi.org/10.1165/rcmb.2018-0324OC

Article  PubMed  PubMed Central  CAS  Google Scholar 

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC, American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 1(5):e44–e68. https://doi.org/10.1164/rccm.201807-1255ST

Article  Google Scholar 

Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, Cooper BG, Culver B, Derom E, Hall GL, Hallstrand TS, Leuppi JD, MacIntyre N, McCormack M, Rosenfeld M, Swenson ER (2022) ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 13(1):2101499. https://doi.org/10.1183/13993003.01499-2021

Article  Google Scholar 

Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, Stocks J, ERS Global Lung Function Initiative (2012) Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 40(6):1324–1343. https://doi.org/10.1183/09031936.00080312

Article  PubMed  PubMed Central  Google Scholar 

Stanojevic S, Graham BL, Cooper BG, Thompson BR, Carter KW, Francis RW, Hall GL, Global Lung Function Initiative TLCO working group; Global Lung Function Initiative (GLI) TLCO (2017) Official ERS technical standards: global lung function initiative reference values for the carbon monoxide transfer factor for caucasians. Eur Respir J 56(4):1750010. https://doi.org/10.1183/13993003.50010-2017

Article  Google Scholar 

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2016) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 193(10):1185. https://doi.org/10.1164/rccm.19310erratum

Article  Google Scholar 

Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE Jr, Collard HR (2012) A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 156(10):684–691. https://doi.org/10.7326/0003-4819-156-10-201205150-00004

Article  PubMed  Google Scholar 

Chandel A, King CS, Ignacio RV, Pastre J, Shlobin OA, Khangoora V, Aryal S, Nyquist A, Singhal A, Flaherty KR, Nathan SD (2023) External validation and longitudinal application of the DO-GAP index to individualise survival prediction in idiopathic pulmonary fibrosis. ERJ Open Res 9:00124–2023. https://doi.org/10.1183/23120541.00124-2023

Article  PubMed  PubMed Central  Google Sch